Information regarding direct contact details for Onivyde is not publicly available.
Who Manufactures Onivyde?
Onivyde is manufactured by Ipsen [1].
How is Onivyde Administered?
Onivyde is administered intravenously [1].
What is Onivyde Used For?
Onivyde is used in combination with leucovorin and fluorouracil to treat adult patients with metastatic pancreatic adenocarcinoma whose disease has progressed on or after gemcitabine-based chemotherapy [1].
What are the Potential Risks of Onivyde?
Onivyde can cause serious side effects, including diarrhea, which can be severe and lead to dehydration or electrolyte imbalances. It can also cause neutropenia and other infections. Patients may experience nausea, vomiting, or stomatitis [1].
How Does Onivyde Work?
Onivyde is a liposomal formulation of irinotecan hydrochloride, a topoisomerase I inhibitor [1]. The liposomal encapsulation is intended to alter the distribution and prolong the exposure of irinotecan to tumor cells [1].
When Did Onivyde Receive FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Onivyde for the treatment of metastatic pancreatic adenocarcinoma in October 2015 [1].
What is the Patent Status of Onivyde?
Information on the specific patent status and expiration dates for Onivyde is available through specialized drug patent tracking resources. For detailed patent information, DrugPatentWatch.com can be a valuable resource [2].